A sick dog, a desperate owner, and multiple chatbots created a compelling story, but the true science was far more complex. When an Australian tech entrepreneur claimed that ChatGPT helped save his dog from cancer, the tale quickly spread, highlighting the hope that AI might revolutionize medicine. However, reality proved more intricate.
Sydney-based Paul Conyngham discovered in 2024 that his dog, Rosie, had cancer. Traditional treatments slowed but didn’t eliminate the tumors. After being told by vets that nothing further could be done, Conyngham asserted that he decided to search for a cure himself.
He utilized ChatGPT to explore treatment possibilities, stumbling on immunotherapy as an option. This led him to experts at the University of New South Wales, who genetically profiled Rosie’s cancer. With input from UNSW professor Pall Thordarson, and aided by Google’s AlphaFold, a personalized mRNA vaccine was devised for Rosie. Thordarson considered it the first such treatment designed for a canine.
Conyngham observed that following an injection, Rosie’s tumors shrank, and she regained some vigor. Despite the improvement, he acknowledged it wasn’t a cure but provided Rosie with more time and better quality of life.
As the story spread, details were lost. Headlines suggested an owner invented a cancer cure using ChatGPT. Social media amplified the narrative, often misrepresenting Rosie’s treatment as a groundbreaking AI achievement. Grok, OpenAI, and others were credited but their exact contributions to the vaccine’s design remained unclear. In practice, the development required significant human expertise and resources, not merely chatbots or AI tools.
AI’s role was more about assisting in research rather than directly designing a treatment. Experts cautioned that the role of AlphaFold and Grok in creating vaccines was overstated. They were supportive tools rather than autonomous designers. The case exemplifies AI facilitating scientific access but not guaranteeing care accessibility, especially given the expertise and costs involved.
Paul Conyngham’s initiative underscores a vision for democratizing access to cancer treatment for pets. However, Rosie’s story is more of a unique and specialized example rather than a replicable template for the masses. The journey relied on prominent expert collaborations and substantial investments to transition from idea to tangible treatment. AI is enhancing scientific engagement, but the gap between this and practical, affordable care persists.